Alpha 2.0
Login Register
» Authors » Georgia Anguera

Georgia Anguera

Explore the profile of Georgia Anguera including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 126
Followers 0
Related Specialties
Oncology
Urology
Pharmacology
Top 10 Co-Authors
Pablo Maroto
Silvia Vidal
Margarita Majem
Ivana Sullivan
Javier Gavira
Alberto Cascon
Carlos Zamora
Agusti Barnadas
Cristina Montero-Conde
Cristina Rodriguez-Antona
Published In
Clin Genitourin Cancer
Clin Transl Oncol
Biomedicines
Int J Cancer
Cancer Immunol Immunother
Affiliations
Soon will be listed here.
Recent Articles
11.
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
de Velasco G, Alonso-Gordoa T, Rodriguez-Vida A, Anguera G, Campayo M, Pinto A, et al.
Clin Genitourin Cancer . 2023 Jan; 21(3):e166-e174. PMID: 36610891
Introduction: The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics...
12.
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
Alserawan L, Anguera G, Zamora Atenza C, Serra Lopez J, Martinez-Martinez L, Riudavets Melia M, et al.
Int J Mol Sci . 2022 Oct; 23(20). PMID: 36293498
Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the...
13.
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Zamora Atenza C, Anguera G, Riudavets Melia M, Alserawan De Lamo L, Sullivan I, Barba Joaquin A, et al.
Cancer Immunol Immunother . 2022 Jan; 71(8):1823-1835. PMID: 34984538
Background: Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1 expression predicts responsiveness, clinical benefit has been observed regardless...
14.
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Pinto A, Reig O, Iglesias C, Gallardo E, Garcia-Del Muro X, Alonso T, et al.
Clin Genitourin Cancer . 2021 Nov; 20(1):25-34. PMID: 34789409
Background: Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increased benefit from...
15.
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
Canto E, Faba O, Zamora C, Mulet M, Garcia-Cuerva M, Palomino A, et al.
Biomedicines . 2021 Sep; 9(9). PMID: 34572311
Background: Bladder cancer (BC) is the ninth most common malignancy worldwide, with high rates of recurrence. The use of urine leukocyte composition at the time of radical cystectomy (RC) as...
16.
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma
Santos M, Lanillos J, Roldan-Romero J, Caleiras E, Montero-Conde C, Cascon A, et al.
Genet Med . 2021 Jan; 23(4):698-704. PMID: 33442023
Purpose: Germline pathogenic variants are estimated to affect 3-5% of renal cell carcinoma (RCC) patients. However, higher mutational prevalence in non-clear cell RCC (non-ccRCC) and advanced disease has been suggested....
17.
Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
Zamora C, Riudavets M, Anguera G, Alserawan L, Sullivan I, Barba A, et al.
Cancer Immunol Immunother . 2021 Jan; 70(6):1691-1704. PMID: 33388994
Background: Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed to analyze...
18.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, et al.
Front Oncol . 2020 Oct; 10:1677. PMID: 33014837
Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to...
19.
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome
Roldan-Romero J, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, et al.
Mod Pathol . 2020 Jul; 33(12):2580-2590. PMID: 32616874
Chromophobe renal cell carcinoma (chRCC) is a histologically and molecularly distinct class of rare renal tumor. TCGA studies revealed low mutational burden, with only TP53 and PTEN recurrently mutated, and...
20.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Marin-Aguilera M, Reig O, Mila-Guasch M, Font A, Domenech M, Rodriguez-Vida A, et al.
Int J Cancer . 2019 Feb; 145(7):1970-1981. PMID: 30807643
TMPRSS2-ERG expression in blood has been correlated with low docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to prospectively asses its role as a taxane-resistance biomarker...